Analyze Diet

Phenylbutazone toxicosis in equidae: a biochemical and pathophysiological study.

Abstract: Toxic effects of phenylbutazone (PBZ) in ponies and horses were studied, using a variety of biochemical, pathophysiologic, and pathologic methods. At dosage levels of 10 to 12 mg/kg of body weight/day for 8 to 10 days, ponies frequently developed clinical signs of toxicosis characterized by hypoproteinemia. Studies using 51CrCl3 demonstrated that PBZ caused a protein-losing gastroenteropathy. The plasma loss was usually associated with gastrointestinal ulceration, but sometimes occurred without obvious lesions in mildly affected animals. Similar studies (8.2 mg/kg/day for 13 days) in Thoroughbreds indicated that they were less susceptible to PBZ toxicity; however, a degree of hypoproteinemia occurred in 4 of 6 treated Thoroughbreds.
Publication Date: 1981-10-01 PubMed ID: 7325437
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research studies the toxic effects of a drug called phenylbutazone, commonly used in horses and ponies, using multiple methods. It highlights how the tested animals often showed signs of poisoning, associated with reduced protein in the body and resulted frequently in protein-losing gastroenteropathy.

Research Methodology

  • The research was conducted on ponies and horses, with the aim of investigating the toxic effects of phenylbutazone (PBZ). PBZ is a drug that is typically used as a pain reliever for these animals.
  • Various methods were used for the study – these include biochemical, pathophysiological, and pathological methods.
  • The dosage given to ponies was between 10 to 12 mg/kg of body weight per day, for a period of 8 to 10 days.
  • For Thoroughbreds, the given dosage was slightly lower – 8.2 mg/kg of body weight per day, lasting for 13 days.

Findings – Ponies

  • After administering the dosage mentioned above, it was observed that ponies frequently showed clinical signs of toxicosis. This condition is characterized by hypoproteinemia, which involves reduced protein levels in the body.
  • The researchers used a specific radiolabelled compound, 51CrCl3, to study the impact of PBZ and found that it caused a protein-losing gastroenteropathy in ponies.
  • This indicates that the drug PBZ led to gastrointestinal disorders where the pony’s digestive tract was not able to absorb proteins properly and was losing protein.
  • The protein loss was usually associated with gastrointestinal ulceration, which involved the formation of ulcers in the digestive tract.

Findings – Horses (Thoroughbreds)

  • The study revealed that Thoroughbreds were less affected by the toxicity of PBZ than ponies. This was despite them being given a similar dosage regimen, although slightly lower.
  • On the other hand, hypoproteinemia did occur in 4 out of the 6 Thoroughbreds treated with PBZ – signifying that while Thoroughbreds might be less susceptible, they are not immune to PBZ’s toxic effects.

Cite This Article

APA
Snow DH, Douglas TA, Thompson H, Parkins JJ, Holmes PH. (1981). Phenylbutazone toxicosis in equidae: a biochemical and pathophysiological study. Am J Vet Res, 42(10), 1754-1759.

Publication

ISSN: 0002-9645
NlmUniqueID: 0375011
Country: United States
Language: English
Volume: 42
Issue: 10
Pages: 1754-1759

Researcher Affiliations

Snow, D H
    Douglas, T A
      Thompson, H
        Parkins, J J
          Holmes, P H

            MeSH Terms

            • Animals
            • Blood Proteins / analysis
            • Blood Urea Nitrogen
            • Cecum / pathology
            • Colon / pathology
            • Extracellular Space
            • Female
            • Horse Diseases / blood
            • Horse Diseases / chemically induced
            • Horse Diseases / pathology
            • Horses
            • Male
            • Phenylbutazone / blood
            • Phenylbutazone / poisoning

            Citations

            This article has been cited 6 times.
            1. Jacobs CC, Schnabel LV, McIlwraith CW, Blikslager AT. Non-steroidal anti-inflammatory drugs in equine orthopaedics.. Equine Vet J 2022 Jan 25;54(4):636-48.
              doi: 10.1111/evj.13561pubmed: 35076950google scholar: lookup
            2. Banse HE, MacLeod H, Crosby C, Windeyer MC. Prevalence of and risk factors for equine glandular and squamous gastric disease in polo horses.. Can Vet J 2018 Aug;59(8):880-884.
              pubmed: 30104780
            3. Worboys M, Toon E. Phenylbutazone (Bute, PBZ, EPZ): one drug across two species.. Hist Philos Life Sci 2018 Mar 26;40(2):27.
              doi: 10.1007/s40656-018-0191-4pubmed: 29582183google scholar: lookup
            4. Staempfli HR, Townsend HG, Prescott JF. Prognostic features and clinical presentation of acute idiopathic enterocolitis in horses.. Can Vet J 1991 Apr;32(4):232-7.
              pubmed: 17423769
            5. Geor RJ, Petrie L, Papich MG, Rousseaux C. The protective effects of sucralfate and ranitidine in foals experimentally intoxicated with phenylbutazone.. Can J Vet Res 1989 Apr;53(2):231-8.
              pubmed: 2713788
            6. Carrick JB, Papich MG, Middleton DM, Naylor JM, Townsend HG. Clinical and pathological effects of flunixin meglumine administration to neonatal foals.. Can J Vet Res 1989 Apr;53(2):195-201.
              pubmed: 2713784